| __timestamp | Celldex Therapeutics, Inc. | HUTCHMED (China) Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 101881000 | 72049000 |
| Thursday, January 1, 2015 | 4011000 | 110777000 |
| Friday, January 1, 2016 | 102026000 | 156328000 |
| Sunday, January 1, 2017 | 96171000 | 175820000 |
| Monday, January 1, 2018 | 66449000 | 143944000 |
| Tuesday, January 1, 2019 | 42672000 | 160152000 |
| Wednesday, January 1, 2020 | 42534000 | 188519000 |
| Friday, January 1, 2021 | 3068000 | 258234000 |
| Saturday, January 1, 2022 | 1400000 | 311103000 |
| Sunday, January 1, 2023 | 3008000 | 384447000 |
Unleashing insights
In the dynamic landscape of biotechnology, understanding cost structures is pivotal. Over the past decade, HUTCHMED (China) Limited and Celldex Therapeutics, Inc. have showcased contrasting trajectories in their cost of revenue. HUTCHMED's cost of revenue surged by approximately 433% from 2014 to 2023, reflecting its aggressive expansion and scaling strategies. In contrast, Celldex experienced a significant decline of around 97% during the same period, indicating strategic shifts or operational efficiencies. Notably, 2023 marked a peak for HUTCHMED, with costs reaching their highest, while Celldex maintained a leaner cost structure. These trends underscore the diverse strategies employed by biotech firms in navigating market challenges and opportunities. As the industry evolves, monitoring such financial metrics offers invaluable insights into corporate health and strategic direction.
Cost of Revenue Trends: AstraZeneca PLC vs Celldex Therapeutics, Inc.
Cost Insights: Breaking Down Regeneron Pharmaceuticals, Inc. and HUTCHMED (China) Limited's Expenses
Cost of Revenue: Key Insights for Biogen Inc. and HUTCHMED (China) Limited
Cost of Revenue Trends: United Therapeutics Corporation vs HUTCHMED (China) Limited
Comparing Cost of Revenue Efficiency: Halozyme Therapeutics, Inc. vs Celldex Therapeutics, Inc.
Cost of Revenue Comparison: Lantheus Holdings, Inc. vs Celldex Therapeutics, Inc.
Cost of Revenue: Key Insights for Ionis Pharmaceuticals, Inc. and HUTCHMED (China) Limited
PTC Therapeutics, Inc. vs HUTCHMED (China) Limited: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Perrigo Company plc vs Celldex Therapeutics, Inc.
Cost of Revenue Trends: Veracyte, Inc. vs Celldex Therapeutics, Inc.
Cost of Revenue Comparison: MorphoSys AG vs Celldex Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: HUTCHMED (China) Limited vs Viridian Therapeutics, Inc.